RT Book, Section
A1 Manno, Rebecca L.
A1 Yazdany, Jinoos
A1 Tarrant, Teresa K.
A1 Kwan, Mildred
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193125814
T1 Granulomatosis with Polyangiitis
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193125814
RD 2024/04/25
AB Key  Clinical  Updates  in  Granulomatosis  with  PolyangiitisAmerican  College  of  Rheumatology/Vasculitis  Foundation  recommendations  favor  rituximab  as  first-line  induction  therapy.  Cyclophosphamide  may  also  be  used  for  induction  therapy.  Avacopan  is  FDA-approved  as  add-on  treatment  for  severe  ANCA-associated  vasculitis  induction  therapy  in  combination  with  rituximab  or  cyclophosphamide  plus  corticosteroids.For  nonsevere  disease  without  life-  or  organ-threatening  manifestations,  methotrexate  up  to  25  mg  oral  or  subcutaneous  weekly,  plus  corticosteroids  may  be  effective  induction  therapy.Rituximab,  dosed  at  a  fixed  interval  of  1  g  every  6  months  or  500  mg  every  4  months,  is  favored  as  first-line  maintenance  treatment.Chung  SA  et  al.  Arthritis  Rheumatol.  [PMID:  34235894]Jayne  DRW  et  al;  ADVOCATE  Study  Group.  N  Engl  J  Med.  [PMID:  33596356]